← Eichor
Condition: Moderately To Severely Active Ulcerative Colitis Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Moderately To Severely Active Ulcerative Colitis

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

The Purpose of This Study is to Evaluate the Efficacy and Safety of 627 in the Treatment of UC
Phase 2 · 1 location(s) · Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. · NCT07507513An Early-Stage Study in Multiple Clinics of How Afimkibart May Affect the Body's Processing of Medicines That Rely on Cy
Phase 1 · 7 location(s) · Hoffmann-La Roche · NCT07665723LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:
Phase 2 · 147 location(s) · Eli Lilly and Company · NCT07186101A Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative Colitis
Phase 2 · 45 location(s) · Pfizer · NCT05287126A Study of How the Medicine Called "Etrasimod" Works in Children With the Gut Disease Called Ulcerative Colitis
Phase 2 · 25 location(s) · Pfizer · NCT07470879Clinical Trial of TQH3906 Capsules for the Treatment of Adult Patients With Moderately to Severely Active Ulcerative Col
Phase 1 · 30 location(s) · Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharm · NCT06754891A Study of MB-001 in Moderately to Severely Active Ulcerative Colitis
Phase 1/Phase 2 · 1 location(s) · Mage Biologics · NCT07374471A Study of Vedolizumab in Adults With Ulcerative Colitis or Crohn's Disease in the Community Setting
Phase 4 · 101 location(s) · Takeda · NCT06581328A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis
Phase 2 · 259 location(s) · Spyre Therapeutics, Inc. · NCT07012395Comparison of Ustekinumab, Infliximab and Combination Therapy in Moderately to Severely Active Ulcerative Colitis
Phase 2 · 1 location(s) · Medical University of Lodz · NCT06453317A Phase 2 Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of HRS-7085 Tablets in Patients With Inf
Phase 2 · 1 location(s) · Shandong Suncadia Medicine Co., Ltd. · NCT07229950A Study Evaluating the Effects of Filgotinib in Children and Teenagers With Ulcerative Colitis
Phase 3 · 47 location(s) · Alfasigma S.p.A. · NCT06865417A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Col
Phase 3 · 398 location(s) · Janssen Research & Development, LLC · NCT07196748A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis
Phase 2 · 207 location(s) · Eli Lilly and Company · NCT06598943A Study for HSK47388 in Participants With Ulcerative Colitis
Phase 2 · 1 location(s) · Haisco Pharmaceutical Group Co., Ltd. · NCT07335055Study to Assess Change in Disease Activity of Risankizumab Treatment in Adult Participants With Moderate to Severe Ulcer
Phase N/A · 56 location(s) · AbbVie · NCT06764706Study of XmAb942 in Healthy Participants and Participants With Ulcerative Colitis
Phase 1/Phase 2 · 90 location(s) · Xencor, Inc. · NCT06619990Study of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative Colitis
Phase 2 · 129 location(s) · Gilead Sciences · NCT06029972A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)
Phase 4 · 49 location(s) · Takeda · NCT06095128Study of the Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of BCD-261 in Subjects With Modera
Phase 2 · 20 location(s) · Biocad · NCT07080034A Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative Colitis
Phase 3 · 54 location(s) · AbbVie · NCT07071519An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Activ
Phase 3 · 191 location(s) · Sanofi · NCT07184996A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants
Phase 3 · 200 location(s) · Hoffmann-La Roche · NCT06588855LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis
Phase 2 · 258 location(s) · Eli Lilly and Company · NCT07415044Safety and Efficacy of OD-07656 and of Subsequent Vedolizumab Therapy in Moderately to Severely Active Ulcerative Coliti
Phase 2 · 32 location(s) · Odyssey Therapeutics · NCT06850727A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis
Phase 3 · 26 location(s) · Janssen Research & Development, LLC · NCT07577856A Study of AC-101 Tablets in Participants With Moderate to Severe Active Ulcerative Colitis
Phase 1/Phase 2 · 1 location(s) · Accro Bioscience (Suzhou) Limited · NCT07083193A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Seve
Phase 2 · 103 location(s) · Genentech, Inc. · NCT06979336A Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Afimkibart (RO7790121) in Children With Moderately to S
Phase 3 · 15 location(s) · Hoffmann-La Roche · NCT07158242An Observational Study to Evaluate Effectiveness and Safety of Upadacitinib in Chinese Adult Participants With Moderate
Phase N/A · 3 location(s) · AbbVie · NCT06838845
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.